Kasmintan A. Schrader

Oct 11, 2023 | nature.com | Dean A. Regier |William D. Foulkes |Kasmintan A. Schrader |Aly Karsan |Raymond Kim

AbstractHereditary cancer syndromes (HCS) predispose individuals to a higher risk of developing multiple cancers. However, current screening strategies have limited ability to screen for all cancer risks. Circulating tumour DNA (ctDNA) detects DNA fragments shed by tumour cells in the bloodstream and can potentially detect cancers early. This study aimed to explore patients’ perspectives on ctDNA’s utility to help inform its clinical adoption and implementation.